News | January 22, 2022
USFDA expands use of Remdesivir for Covid-19
Previously, the use of the drug was limited to patients requiring hospitalization
Previously, the use of the drug was limited to patients requiring hospitalization
UCB plans to submit regulatory applications in Q3 2022
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Biocon has reported consolidated financial results for the period ended December 31, 2021
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
However, these won’t be available at the nearest chemist store soon
Subscribe To Our Newsletter & Stay Updated
